cancer-stem-cells-2018-scientifictracks

J u n e 1 1 - 1 3 , 2 0 1 8 | D u b l i n , I r e l a n d

allied

academies

Page 58

Note:

CANCER STEM CELLS AND

ONCOLOGY RESEARCH

International Conference on

Journal of Medical Oncology and Therapeutics

Volume 3

Seong-Jin Kim, J Med Oncl Ther 2018, Volume 3

TGF-β SIGNALING IS A NOVEL

THERAPEUTIC TARGET FOR TREATING

METASTATIC CANCERS ACQUIRED BY

EMT AND CANCER STEMNESS

Seong-Jin Kim

Seoul National University, Korea

GF-β is amultifunctional cytokine involved in diverse cellular functions,

including cell growth and immune responses. TGF-β signaling has

emerged as a key architect of the microenvironment in poor-prognosis

cancers. Disseminated tumor cells show a strong dependency on a TGF-

β-activated stromal during the establishment and subsequent expansion

of metastasis. TGF-β also has a positive role on the cancer stem cell

(CSC) population promoting or sustaining stemness of the pool of CSCs in

diverse types of malignancy. Since TGF-β signaling is dysregulation most

of human cancers, thus affecting the overall progression to malignancy,

TGF-β signaling has been considered a potentially novel therapeutic target

for treating resistance acquired by emptying the TGF-β signaling pathway,

TGF-β receptor I kinase inhibitors have shown promise in blocking the

TGF-β-mediated tumor progression and metastasis and enhancing

antitumor immunity in nonclinical animal models. Vactosertib, a TGF-β

receptor I kinase inhibitor, has shown significant preclinical antitumor

efficacy in a range of in vivo metastatic and orthotopic xenograft models

and has completed phase 1 clinical trials in USA. Recent molecular

classification of gastrointestinal cancer has identified a poor-prognosis

transcriptional subtype associated with mesenchymal traits and genes

upregulated by TGF-β in stromal cells are robust predictors of cancer

recurrence and metastasis. This observation warrants the development

of anti-TGF-β therapies for the treatment of poor-prognosis cancers with

TGF-β response signature.

Seong-Jin Kim is currently working as a profes-

sor at the PrecisionMedicine Research Center at

the Advanced Institute of Convergence Technol-

ogy, Seoul National University, Korea.

BIOGRAPHY